New research reveals that resistant myeloma cells import putrescine through the transporter SLC45A4, activating HOXA1-driven ...

Certain gut bacteria and their genes were linked to cancer outcomes and chemotherapy side effects. Credit: Shutterstock Gut bacteria may hold clues to cancer survival and chemotherapy side effects ...

The Blood Cancer United Specialized Center of Research (SCOR) Program 2026–2027 supports multidisciplinary teams pursuing ...

A study of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with ...

Exploring T-Cell Engager Therapy for Multiple Myeloma - Moffitt Cancer Center / cancer, Cell Coast 2026, Ken Shain, Moffitt ...

Bristol Myers Squibb (NYSE:BMY) reported new Phase 3 EXCALIBER-RRMM data for its Zenbexus combination in relapsed or ...

GSK agreed on September 15, 2026, to acquire full global rights to a Chimagen Biosciences trispecific T-cell engager for multiple myeloma in a deal worth up to USD 750 million. According to Markets ...

A paired study of 44 multiple myeloma patient-caregiver dyads in Seoul finds that patients and caregivers face nearly ...

The NIH is placing a "big bet" on an accelerated initiative for therapeutic cancer vaccines, most of which use mRNA ...

BMS said the safety profile of ZENBEXUS in combination with standard therapies was consistent with previously reported ...

African American patients with newly diagnosed multiple myeloma were less likely than White patients to receive drugs that ...